title: [Achievement of cardiovascular prevention goals, pharmacologic prescription and major cardiovascular events among patients with coronary disease].
abstract: BACKGROUND
  Implementation of health programs to reduce cardiovascular risk, are needed for secondary prevention of cardiovascular diseases.
  
  
  OBJECTIVE
  To evalúate achievements of secondary prevention goals, pharmacologic prescription and major cardiovascular events in patients with coronary artery disease.
  
  
  METHODS
  Patients who had a first event of acute coronary syndrome, angioplasty or revascularization surgery, between January 2008 and June 2010, were contacted for a clinical and laboratory evaluation between June and October 2011.
  
  
  RESULTS
  Seven hundred and two medical records were reviewed and 245 eligible patients were identified. Of these, we assessed 202 patients aged 64 ± 10 years (70% males). Sixty seven percent had two or more cardiovascular risk factors. A goal of HDL cholesterol level over 40 mg/dL was achieved in 91 % of patients, smoking cessation in 84% and a total cholesterol < 200 mg/dL in 66%. A blood pressure below 130/85 mm Hg was achieved in 30% of patients, a normal BMI in 19% and LDL cholesterol levels below 70 mg/dL in 18%. At the moment of assessment, 87%> were using aspirin, 78%> statins, 74% angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists and 66%o were using β--blockers. Twenty two percent of patients had a major cardiovascular event during the follow up, which lasted 28 ± 8 months.
  
  
  CONCLUSIONS
  A low percentage of cardiovascular goals achievement was observed in this sample of patients, with a high prevalence of overweight and obesity. A high percentage quit smoking after their first cardiovascular event. Despite the high percentage of drug prescription, hypertension and dyslipidemia were not fully controlled.
authors.affiliation: Universidad de La Frontera, Temuco, Chile.
authors.forename: Víctor
authors.initials: V
authors.lastname: Neira V
authors.affiliation: Universidad de La Frontera, Temuco, Chile.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Potthoff N
authors.affiliation: Universidad de La Frontera, Temuco, Chile.
authors.forename: Luis
authors.initials: L
authors.lastname: Quiñiñir S
authors.affiliation: Universidad de La Frontera, Temuco, Chile.
authors.forename: Gabriel
authors.initials: G
authors.lastname: López R
authors.affiliation: Hospital Dr. Hernán Henríquez Aravena, Universidad de La Frontera, Temuco, Chile.
authors.forename: Benjamín
authors.initials: B
authors.lastname: Stockins F
authors.affiliation: Hospital Dr. Víctor Ríos Ruiz, Los Ángeles, Chile.
authors.forename: Carlos
authors.initials: C
authors.lastname: Castillo B
authors.affiliation: Hospital Dr. Hernán Henríquez Aravena, Universidad de La Frontera, Temuco, Chile.
authors.forename: Fernando
authors.initials: F
authors.lastname: Lanas Z
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D003327:Coronary Disease / Q000188:drug therapy; D003430:Cross-Sectional Studies; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D006040:Goals; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012959:Socioeconomic Factors